PCSK9 Inhibitors: A New Class of Cholesterol Busters
Flashback: A Review of Statins
By now you've heard of statins, also known as HMG-CoA reductase inhibitors. Statins are the cornerstone of treatment to help regulate cholesterol production. Available since the late 1980's, statins include well-known blockbusters like atorvastatin (Lipitor), simvastatin (Zocor), and rosuvastatin (Crestor).
Statins work so well because they inhibit an enzyme involved in the making of cholesterol in the liver and boost the number of low density lipoprotein (LDL) receptors to help clear the body of LDL ("bad cholesterol). However, as researchers have reported in Annals of Internal Medicine, a new class of drugs may change the face of lowering LDL cholesterol.
What Are PCSK9 Inhibitors?
The PCSK9 inhibitors (PSK9i) are a class of injectable drugs approved in 2015 that have been shown to dramatically lower LDL cholesterol levels, by up to 60% when combined with a statin.
PCSK9 inhibitors are monoclonal antibodies (MABs), a type of biologic drug. They bind to and inactivate a protein in the liver called proprotein convertase subtilisin kexin 9 (PCSK9). It's importsnt to block PCSK9 because it inactivates the needed receptors on the liver cell surface that transport LDL into the liver for metabolism (break down). Without these receptors, more LDL ("bad" cholesterol) remains in the blood.
So, by inactivating PCSK9 via inhibition, more receptors are available to capture LDL for break down and removal from the blood. And, as we know, lower LDL is better for the heart.
Who Needs a PCSK9 Inhibitor?
According to the latest Centers for Disease Control and Prevention (CDC) facts, about one-third, or 71 million American adults have high levels of low-density lipoprotein (LDL), or “bad,” cholesterol. However, only 1 out of every 3 adults with high LDL is receiving adequate treatment. Less than half of adults with high LDL cholesterol get treatment. In addition, there are about 11 million people who cannot reach their LDL cholesterol goals, even though they have been on a first-line treatment like statins.
In fact, about 1 in 5 patients on statins cannot lower their cholesterol adequately at all; some due to serious genetic defects. In addition, some patients stop their statin treatment due to side effects. PCSK9 inhibitors may be used alone or in combination with statins like Lipitor or Crestor to further lower the hardest-to-treat elevated cholesterol levels for patients who cannot tolerate any statin drug due to side effects.
Clinical Studies for PCSK9 Inhibitors
Several PCSK9 studies were published in the New England Journal of Medicine (NEJM) show that two agents, evolocumab (Repatha) or alirocumab (Praluent), when combined with statins, lower cholesterol better than the statin alone.
After one year, those patients who were taking both the PCSK9 inhibitor and the statin together had LDL levels that were at least 60 percent lower than the group taking only statins. LDL levels dropped dramatically. Larger studies are ongoing to evaluate PCSK9 inhibitors on the ability to lower outcomes like heart attack or stroke, but early results suggest cardiovascular events could be lowered by half.
PCSK9 Inhibitors: Just the Basic Facts
PCSK9 inhibitors are given by subcutaneous (under the skin) injection, via self-administration with a pen device, one or two times per month. In general, PCSK9 inhibitors have been well-tolerated, but the common cold, itching, flu, injection site reactions, and serious allergic reactions have been reported. Injection site reactions are the most common reaction but infrequently lead to discontinuation of treatment.
More studies of a larger population size are ongoing to fully define outcomes like prevention of heart attack, stroke, and other cardiovascular disease. These drugs are monoclonal antibodies (MABs), an expensive drug type, and cost roughly $14,000 per year (cash price without insurance) in the US. They are also approved in the European Union.
Praluent (alirocumab) by Sanofi/Regeneron
In July 2015, alirocumab (Praluent) by Sanofi and Regeneron was the first PCSK9 inhibitor to receive an FDA-approval. Clinical studies included ODYSSEY, an 18-month, phase 3 trial of 2,341 high-risk patients with high cholesterol on statin therapy. LDL was reduced over 60 percent after 24 weeks, and remained low over 78 weeks.
The incidence of pre-specified cardiac adverse events like heart attack or stroke were lower in the alirocumab group (1.7%) compared to placebo (3.3%), but full cardiovascular outcomes are not known yet. The labeling states that the effect of Praluent on cardiovascular morbidity and mortality has not been determined. Ongoing trials with Praluent are assessing cardiovascular outcomes like heart attack or stroke. Investigators are looking at a composite endpoint of heart disease death, heart attacks, strokes (fatal and non-fatal), and angina. Final trial results from Sanofi/Regeneron are expected in late 2017 or 2018.
Praluent Side Effects
Praluent (alirocumab) was evaluated in five placebo-controlled trials involving 2,476 patients. All patients had HeFH or were otherwise at high risk for heart attack or stroke, and were taking maximally tolerated doses of a statin. Participants taking Praluent had an LDL reduction from 36 to 59 percent compared to placebo.
The most common side effects have included nasopharyngitis (common cold), injection site reactions, and influenza. Serious allergic reactions were also reported.
For a full list of side effects with Praluent, go here.
Repatha (evolocumab) by Amgen
Repatha (evolocumab) was FDA-approved in August of 2015.
Repatha injection is for use in addition to diet and maximally-tolerated statin therapy in adult patients with primary hyperlipidemia such as:
- heterozygous familial hypercholesterolemia (HeFH)
- clinical atherosclerotic cardiovascular disease (ASCVD), such as a heart attack or stroke, who require additional lowering of LDL cholesterol.
Repatha is also used in addition to diet and other LDL-lowering therapies (e.g., statins, ezetimibe, LDL apheresis) for the treatment of patients with Homozygous Familial Hypercholesterolemia (HoFH) who require additional lowering of LDL-C.
In Phase 3 clinical trials, Repatha lowered LDL by roughly 60% across all study groups in 12 week and 52-week studies; Repatha reduced LDL cholesterol levels by 61% (from a median of 120 mg/dL to 48 mg/dL over 12 weeks. In HoFH, Repatha reduced LDL by 31%.
Side Effects with Repatha
In the OSLER-1 and OSLER-2 open-label studies, side effects that occurred with Repatha at a rate of at least 1% included arthralgia (joint pain, 4.6%), injection site reactions (4.3%), headache (3.6%), limb pain (3.3%), and fatigue (2.8%). Injection site reactions rarely lead to discontinuation of PCSK9 inhibitors.
Neurocognitive effects like confusion were low (under 1%). Evolocumab was stopped in 7.2% of 2976 patients. Very low levels of LDL did not appear to affect rates of side effects. Other side effects include the common cold, upper respiratory tract infections, and injection site reactions. No clinically important drug interactions have been identified with Repatha.
To see a detailed list of side effects, visit here.
The recommended dose of Repatha (evolocumab):
- 140 mg subcutaneously (abdomen, thigh, or upper arm) every two weeks or 420 mg once monthly for primary hyperlipidemia with established clinical atherosclerotic CVD or heterozygous familial hypercholesterolemia (HeFH).
- For homozygous familial hypercholesterolemia (HoFH), the approved dose is 420 mg subcutaneously once monthly or 420 mg every two weeks.
The initial dose of Praluent (alirocumab):
- 75 mg subcutaneously once every two weeks; most patients will achieve adequate LDL lowering with this dose. If preferred, 300 mg once every 4 weeks (monthly) may be given.
Ongoing PCSKi Questions
Analysts predict that Repatha and Praluent could each generate annual sales of over $1 billion by 2020, but due to lack of data on cardiovascular outcomes sales have been sluggish.
Managed care experts suggest this new class of drug could add considerable costs to statin therapy - which primarily exist in generic and very affordable form now. However, this treatment targets the highest-risk patients who cannot reach adequate LDL levels with statins and may have run out of options.
In May 2017, Amgen reported on the 27,564-patient phase 3, Fourier trial, designed to answer if the addition of Repatha to high-intensity statin therapy reduces major cardiovascular events compared to placebo in patients with atherosclerosis. At a median of 26 months, Repatha consistently reduced the risk of the composite primary endpoint, which included hospitalization for unstable angina, coronary revascularization, heart attack, stroke or cardiovascular death, regardless of whether baseline LDL-C was below or above 70 mg/dL (20% reduction in patients with baseline <70 mg/dL; 14% reduction if baseline ≥70 mg/dL). LDL was reduced by 59%, but Repatha had no significant effect on cardiovascular mortality or hospitalization for unstable angina.
Bococizumab Studies Halted
In November 2016, Pfizer discontinued the global development of bococizumab, their investigational PCSK inhibitor, as well as the two ongoing cardiovascular outcome studies, SPIRE-1 and SPIRE-2.
Pfizer stated that unexpected results occurred in looking at the outcomes of six Phase III studies. Compared to current agents in this class, LDL lowering over time with bococizumab was not as robust, and a higher level of immunogenicity and a higher rate of injection-site reactions also occurred. Due to lack of value to shareholders, especially in the currently marketplace, Pfizer decided to halt the studies worldwide.
Alternate Mechanisms: PCSK9
In addition to blocking the PCSK9 receptor to lower LDL, blocking the synthesis of PCSK9 can lower LDL levels. Synthesis of PCSK9 requires mRNA. Phase I dose-ranging studies have looked at degradation of the mRNA needed for PCSK9 development with a compound called ALN-PCS (inclisiran) from Alnylam Pharmaceuticals/The Medicines Company.
In a Phase I study published in the New England Journal of Medicine in early 2017, inclisiran (ALN-PCS) doses of 300 mg or more (in single or multiple doses) significantly reduced levels of PCSK9 (~75%) and LDL cholesterol (~50%) for at least 6 months. The most common adverse events were cough, musculoskeletal pain, cold/runny nose, headache, back pain, and diarrhea. Further studies to investigate effectiveness, safety and long-term use, and FDA-approval, will need to be completed before clinical use.
Lifestyle is Still an Important Adjunct
Everyone should partake in a healthy lifestyle, whether they have high cholesterol or not. We know you've heard this before, but it really is important:
- Quit smoking
- Eat a low fat, low salt diet
- Exercise 30 to 40 minutes a day on most days of the week
- Control your stress, learn to relax
Finished: PCSK9 Inhibitors: A New Class of Cholesterol Busters
- Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017 May 4;376(18):1713-1722. doi: 10.1056/NEJMoa1615664. Epub 2017 Mar 17.
- Praluent Prescribing Information. Regeneron, Sanofi. Revised July 2015. Accessed 1/13/2017 at http://products.sanofi.us/praluent/praluent.pdf.
- Seidah NG. Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors in the treatment of hypercholesterolemia and other pathologies (abstract). Curr Pharm Des. 2013;19(17):3161-72. Accessed 1/13/2017 at http://www.ncbi.nlm.nih.gov/pubmed/23317404
- Gouni-Berthold I, Berthold HK. PCSK9 Antibodies for the Treatment of Hypercholesterolemia. Nutrients. 2014 Dec; 6(12): 5517–5533. Accessed 1/13/2017 at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4276981/
- Seidah NG, Awan Z, Chrétien M, Mbikay M. PCSK9 - A Key Modulator of Cardiovascular. Circulation Research. 2014; 114: 1022-1036. Accessed 1/13/2017 at Healthhttp://circres.ahajournals.org/content/114/6/1022.long
- Pfizer 3Q Earnings Up. Drugs.com. Accessed March 22, 2015 at https://www.drugs.com/news/pfizer-3q-earnings-up-48526.html
- Bidness, Etc. Amgen, Inc., Sanofi SA (ADR)-Regeneron Pharmaceuticals Inc PCSK9 Inhibitors: The Next Big Change In The Heart Disease Market. Accessed 1/13/2017 at http://www.bidnessetc.com/36965-amgen-inc-sanofi-sa-adrregeneron-pharmaceuticals-inc-pcsk9-inhibitors-the-n/
- Curfman, G. PCSK9 inhibitors: a major advance in cholesterol-lowering drug therapy. Harvard Health Publications. March 15, 2015. Accessed 1/13/2017 at http://www.health.harvard.edu/blog/pcsk9-inhibitors-a-major-advance-in-cholesterol-lowering-drug-therapy-201503157801
- Marketwatch. Amgen, other drug company shares jump on cholesterol drug findings. March 16, 2015. Accessed 1/13/2017 at http://www.marketwatch.com/story/amgen-other-drug-company-shares-jump-on-cholesterol-drug-findings-2015-03-16
- Kastelein J, et al. JPCSK9 inhibitors: Pharmacology, adverse effects, and use. UpToDate. Accessed 1/13/2017 at https://www.uptodate.com/
- Fitzgerald K, et al. A Highly Durable RNAi Therapeutic Inhibitor of PCSK9. N Engl J Med. 2017 Jan 5;376(1):41-51. Accessed 1/13/2017 at https://www.ncbi.nlm.nih.gov/pubmed?term=27959715